AMARIN CORP PLC\UK Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
AMARIN CORP PLC\UK (AMRN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $267.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2021-02-25
- AMARIN CORP PLC\UK effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2018 was $267.00K.
- AMARIN CORP PLC\UK effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2017 was -$17.00K, a 100.88% decline from fiscal 2016.
- AMARIN CORP PLC\UK effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2016 was $1.92M, a 20.58% increase from fiscal 2015.
- AMARIN CORP PLC\UK effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2015 was $1.59M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2018-12-31 | $267.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | -$17.00K 10-K · filed 2020-02-25 |
| 2016-12-31 | $1.92M 10-K · filed 2019-02-27 |
| 2015-12-31 | $1.59M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |